Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silexion Therapeutics Corp (SLXN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a clinical-stage biotechnology issuer listed on the Nasdaq Capital Market. Silexion files current reports on Form 8-K, registration statements, and other documents that describe its RNA interference (RNAi) programs for KRAS-driven cancers, financing activities, and corporate developments.
Through its Form 8-K filings, Silexion furnishes press releases on key events such as positive preclinical data for its lead siRNA candidate SIL204, completion of toxicology studies, written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on its planned Phase 2/3 trial in locally advanced pancreatic cancer, and submission of a clinical trial application in Israel. Other 8-Ks detail capital-raising transactions, including public offerings and an at-the-market offering agreement, as well as Nasdaq correspondence confirming restoration of compliance with minimum bid price and shareholders’ equity listing requirements.
Investors can also review registration statements such as the Form S-1, which outlines Silexion’s status as a Cayman Islands–incorporated emerging growth company, its ordinary share and warrant structures, and risk disclosures associated with its clinical-stage oncology business. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide additional information on research and development expenses, general and administrative costs, and accumulated deficit.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand new financings, regulatory milestones, and material agreements. Real-time updates from EDGAR, along with structured access to Forms 8-K, registration statements, and other filings, allow users to track how Silexion describes its KRAS-focused RNAi pipeline, clinical plans for SIL204, and capital resources in its official SEC disclosures.
Silexion Therapeutics Corp filed a current report to share news about its pancreatic cancer program. On December 2, 2025, the company issued a press release titled “Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer.” This indicates that a German health authority has responded favorably to the company’s proposed design for a Phase 2/3 study, an important planning step before running a larger, later-stage trial.
The company is furnishing this press release under a Regulation FD disclosure, meaning it is providing the information broadly to the market. The disclosure is explicitly described as “furnished” rather than “filed,” so it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Silexion Therapeutics Corp (SLXN) announced that it has successfully completed toxicology studies for SIL204, its next-generation RNA silencing therapy. These studies are a key safety step that supports moving SIL204 into a planned Phase 2/3 clinical trial in pancreatic cancer, a disease with limited treatment options. The update was provided through a press release that is included as an exhibit to this report.
The company’s ordinary shares and related warrants continue to trade on The Nasdaq Stock Market under the symbols SLXN and SLXNW, respectively. The disclosure is furnished under Regulation FD, meaning it is intended to provide broad, simultaneous information to the market rather than to update the company’s formal financial statements.
Silexion Therapeutics Corp announced it issued a press release with financial results for the third quarter ended September 30, 2025, and furnished the release as Exhibit 99.1. The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in future filings.
Silexion’s securities listed on Nasdaq include Ordinary Shares (par value $0.0135) under ticker SLXN and Warrants (exercise price $1,552.50) under ticker SLXNW.
Silexion Therapeutics Corp (SLXN) filed its quarterly report detailing continued operating losses and new financing capacity. For the nine months ended September 30, 2025, the company reported a net loss of $7.5 million on operating expenses of $7.2 million. Cash and cash equivalents increased to $9.243 million as of September 30, 2025, up from $1.187 million at year‑end, driven by equity raises and warrant exercises.
The balance sheet shifted to shareholders’ equity of $6.977 million from a deficit at December 31, 2024. During 2025, the company completed public offerings with aggregate gross proceeds of approximately $5.0 million in January and $6.0 million in September, plus additional gross proceeds from warrant exercises, including $1.78 million tied to September warrants. It also established an ATM program up to $13.17 million and has an effective S‑3 shelf up to $100 million.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern given ongoing losses and expected negative operating cash flows. Reverse share splits of 1‑for‑9 and 1‑for‑15 were effected in November 2024 and July 2025, respectively. Shares outstanding were 3,126,642 as of November 9, 2025.
Silexion Therapeutics Corp (SLXN) filed a resale registration covering up to 1,292,348 ordinary shares and up to 372 warrants for sale by selling securityholders. The company will not receive proceeds from these sales; it may receive up to $4.9 million only if holders exercise 344,063 registered warrants for cash.
The registered shares comprise up to 473,576 existing shares, up to 344,063 shares issuable upon warrant exercise, and up to 474,709 shares issuable upon conversion of a convertible promissory note (assuming a $3.44 per‑share conversion price as disclosed). Ordinary shares outstanding were 3,126,642 as of the date hereof. If all registered warrants are exercised for shares and the assumed full note conversion occurs, shares outstanding could reach up to 3,945,414.
SLXN ordinary shares and warrants trade on Nasdaq as “SLXN” and “SLXNW.” On October 29, 2025, the last reported prices were $3.44 per share and $0.04 per warrant. The filing states investing involves a high degree of risk; see the risk factors for details.
Silexion Therapeutics Corp filed a current report to share new preclinical research results for its drug candidate SIL204. On September 30, 2025, the company issued a press release titled “Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer.”
The report states that new human cell line data confirm pan-KRAS activity for SIL204, with inhibition reported as high as 99.7%, and describes first evidence related to gastric cancer. The press release is furnished as Exhibit 99.1, and this information is provided under Regulation FD as “furnished,” not “filed,” which limits its use in certain legal contexts.
Silexion Therapeutics Corp is a Cayman Islands clinical-stage biotech focused on RNAi silencing of KRAS for KRAS G12D/V locally advanced pancreatic cancer. Their lead candidate, SIL204, is a second-generation siRNA delivered intratumorally plus subcutaneous systemic dosing alongside standard-of-care chemotherapy. The company completed a public offering on September 12, 2025 raising approximately $6.0 million gross and holds an At-The-Market sales agreement to offer up to $13.17 million of ordinary shares through H.C. Wainwright. As of June 30, 2025 pro forma cash was presented and pro forma shareholders’ equity increased after recent financings. Management plans toxicology studies in 2025 and regulatory submissions to support a planned Phase 2/3 randomized trial initiating in H1 2026.
Silexion Therapeutics Corp entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC and filed the agreement as an exhibit. The filing shows the company executed an arrangement to sell shares into the open market over time through the placement agent, providing a flexible means to raise capital as needed. The document includes an executed signature block by the Chief Executive Officer, indicating the agreement is authorized by management.
Silexion Therapeutics Corp. received a Nasdaq Compliance Letter confirming it has met the Nasdaq Capital Market's shareholder equity requirement and minimum $1.00 bid price requirement. The company completed financings that increased pro forma shareholders' equity by $10.3 million to approximately $9.41 million as of September 15, 2025. After a 1-for-15 reverse share split effected July 29, 2025, the closing price of the ordinary shares has been above $1.00. Nasdaq will monitor the company via a mandatory panel monitor through September 23, 2026, and a future equity deficiency during that period could lead to a delist determination and a new hearing opportunity.
Silexion Therapeutics Corp Schedule 13D/A reports that Moringa-related parties disclosed ownership totaling approximately 14.6% of the company's ordinary shares. The filing states Silexion issued 450,000 ordinary shares to Moringa Sponsor, LP on September 15, 2025, in conversion of $1.8 million of an outstanding promissory note, but the Reporting Persons expressly dispute the validity of that issuance and do not concede beneficial ownership of those shares. The cover-page totals combine 6,970 issued ordinary shares, 372 ordinary shares underlying warrants and the 450,000 shares the Reporting Persons contest. The Reporting Persons also reported a pro rata distribution on August 7, 2025 of certain shares and warrants to limited partners.